Zoetis Inc. $ZTS Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB raised its position in Zoetis Inc. (NYSE:ZTS) by 7.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,640 shares of the company’s stock after purchasing an additional 13,883 shares during the period. Handelsbanken Fonder AB’s holdings in Zoetis were worth $31,914,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Nuveen LLC acquired a new stake in Zoetis in the first quarter valued at $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after acquiring an additional 1,995,491 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. Polen Capital Management LLC raised its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its stake in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after purchasing an additional 922,589 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $122.06 on Friday. The firm’s fifty day simple moving average is $137.75 and its 200-day simple moving average is $150.17. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85. The stock has a market capitalization of $53.79 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is 33.67%.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday. Morgan Stanley lowered their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday. They issued a “sector weight” rating on the stock. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, BTIG Research decreased their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.